Global Neurodegenerative Diseases Market Overview:
The brain is a complex organ with a vast number of the pathway that allows doing different activities. Brain is made up of billions of cells which are responsible for every second of everyday proper functioning. Some of the most important cells in the brain are called neurons. Neuron communicates with each other to perform every function of brain whether it involves movement, thinking, talking or remembering of things. When the cell of the brain are closely connected and miscommunicated in one area, it disrupts the other brain activities and leads to disease. Neurodegenerative disease is a term for a range of condition which primarily affects the neurons in the human brain. It occurs when the nerve cell in the brain or peripheral nervous system lose function over time and dies. These diseases are incurable and cause problems with movement or mental functioning (called dementias). The risk of this is being affected by the disease increases with age. Neurodegenerative diseases include Alzheimer's, multiple sclerosis, Huntington's disease, Parkinson's disease, multiple system atrophy, spinal muscular atrophy, and others. Change in lifestyles such as unhealthy eating habits, improper sleeping, and high-stress levels are likely to result in degenerative of nerve cells. Some of the key players profiled in the study are Novartis (Switzerland), Merck Serono (United States), Teva Pharmaceutical (Isreal), Pfizer (United States), Biogen Idec (United States), Bayer Schering Pharma AG (Germany), Boehringer Ingelheim (Germany), Amarin Corporation (Ireland), AstraZeneca (United Kingdom), Alector (United States), Yumanity Therapeutics (United States), Yangtze River Pharmaceutical Group (China) and Chongqing Zein Pharmaceutical (China).
On the basis of geography, the market of Neurodegenerative Diseases has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. N-methyl-D-aspartate Receptor will boost the Neurodegenerative Diseases market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rising Prevalence of Neurological Disorder among All Genders, Races and Geographical Backgrounds
- Increased Focus in Patient-Centric Healthcare Delivery
- Growing Awareness about Neurodegenerative Diseases
- Innovation in Neurodegenerative Disease Drug Discovery
- Remote Monitoring and Growing Focus on Consumer-Centric Mobility Solutions
- Stringent Government Rules and Regulations
- High Cost Associated With Neurodegenerative Disease
- Patent Expiry of Neurodegenerative Disease Treatment Products
- Rising Incidence Due To Change In Lifestyle Such As Improper Sleeping, High-Stress Levels, And Unhealthy Eating Habits
- Dearth of Skilled Professionals to Treat Neurodegenerative Diseases
According to the study of Parkinsonís Association in 2018, around 1.2 million people in the U.S are estimated to be suffering from Parkinsonís disease by 2030. As per the Alzheimerís Association, around 5.4 million Americans were suffering from Alzheimerís in the year 2016. Moreover, this disease is more prevalent among people aged 65 years and above.
Target Audience:Medical Institutes, Industry Association Related to Neurodegenerative Diseases, Government Regulatory Bodies, Government and Private Research Organization and Others
Major Objectives Focused through this Study To define, describe, and forecast the Global Neurodegenerative Diseases market on the basis of product  , application [Alzheimer's Disease, Huntington Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis], key regions and end user
To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
To provide market size for various segments of the Neurodegenerative Diseases market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
To strategically profile the key players and analyzing their market shares and core competencies in the Neurodegenerative Diseases industry
To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market
Available Customization: Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Eisai (Japan), H.Lundbeck A/S (Denmark) and Jiangsu Hansoh Pharmaceutical (China).
** Confirmation on availability of data would be informed prior purchase
While framing the research framework, major and emerging players operating in the Neurodegenerative Diseases market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.